This study showed also that 13 genes were recurrently mutated in prostate cancer, in addition to previously reported recurrent mutations: deletions of SPOP, TP53, FOXA1, PTEN, MED12, and CDKN1B; additional clinically relevant genes were identified with lower frequencies, including BRAF, HRAS, AKT1, CTNNB1, and ATM (Figure 1) [38]. This evidence concerns the gene FOXA1 and prostate carcinoma.